(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 ...
They also looked at results from positron emission tomography, or PET, scans that showed whether the person's brain contained excess tau protein as well as beta amyloid, another Alzheimer's-related ...